Table 3.
Adverse effects more commonly reported in LBSL02, C1056, and C1057 studies-combined analysis [12].
| Symptom | Placebo N = 675 |
Belimumab 1 mg/kg N = 673 |
Belimumab 10 mg/kg N = 674 |
|---|---|---|---|
| Headache | 140 (20.7%) | 138 (20.5%) | 142 (21.1%) |
| Upper airways infection | 130 (19.3%) | 128 (19.0%) | 118 (17.5%) |
| Arthralgia | 112 (16.6%) | 100 (14.9%) | 109 (16.2%) |
| Nausea | 82 (12.1%) | 88 (13.1%) | 99 (14.7%) |
| Urinary tract infection | 82 (12.1%) | 92 (13.7%) | 87 (12.9%) |
| Diarrhea | 62 (9.2%) | 81 (12.0%) | 80 (11.9%) |
| Asthenia | 70 (10.4%) | 71 (10.5%) | 66 (9.8%) |
| Pyrexia | 52 (7.7%) | 52 (7.7%) | 65 (9.6%) |